-
Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors Br. J. Cancer (IF 8.8) Pub Date : 2024-04-18 Ching-Yuan Chang, Bobby L. Jones, Juan M. Hincapie-Castillo, Haesuk Park, Coy D. Heldermon, Vakaramoko Diaby, Debbie L. Wilson, Wei-Hsuan Lo-Ciganic
-
FGFR4-driven plasticity in breast cancer progression and resistance to therapy Br. J. Cancer (IF 8.8) Pub Date : 2024-04-17 Marcin Braun, Dominika Piasecka, Rafal Sadej, Hanna M. Romanska
-
Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses Br. J. Cancer (IF 8.8) Pub Date : 2024-04-15 Jacob Kment, Daniel Newsted, Stephanie Young, Michael C. Vermeulen, Brian J. Laight, Peter A. Greer, Yan Lan, Andrew W. Craig
-
Radiation Reveal: Moving from research engagement to involvement Br. J. Cancer (IF 8.8) Pub Date : 2024-04-13 Lisa Whittaker, Jamie A. Dean, Catarina Veiga, Sophie Langdon, Rebecca Drake, Daniel Taylor, Myfanwy-Cerys Williams, Holly Masters, Alex Britton, Mia Cumbo, Nicole Burdis, Kate Mason, Gemma Fay, Emma Smith, Sam Benson, Alfie Halil, Sophie Lambert, Mark N. Gaze, Jenny Gains, Bella Spencer, Alice Taylor-Gee, Samantha Y. A. Terry
-
Predictable changes in the accuracy of human papillomavirus tests after vaccination: review with implications for performance monitoring in cervical screening Br. J. Cancer (IF 8.8) Pub Date : 2024-04-13 Matejka Rebolj, Adam R. Brentnall, Kate Cuschieri
-
Single-cell sequencing reveals VEGFR as a potential target for CAR-T cell therapy in chordoma Br. J. Cancer (IF 8.8) Pub Date : 2024-04-11 Huantong Wu, Xinqiang Li, Boyan Zhang, Penghao Liu, Maoyang Qi, Yueqi Du, Can Zhang, Wanru Duan, Zan Chen
-
SPP1 represents a therapeutic target that promotes the progression of oesophageal squamous cell carcinoma by driving M2 macrophage infiltration Br. J. Cancer (IF 8.8) Pub Date : 2024-04-10 Chen Wang, Yutong Li, Linhong Wang, Yu Han, Xiaohui Gao, Tiandong Li, Man Liu, Liping Dai, Renle Du
-
Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models Br. J. Cancer (IF 8.8) Pub Date : 2024-04-10 Maryam Arshad, Abul Azad, Phoebe Yuen Ka Chan, Vasanthy Vigneswara, Katharina Feldinger, Siti Norasikin Mohd Nafi, Eloise Laporte-Maguire, Carmela De Santo, Jianmin Zuo, Abeer M. Shaaban, Anthony Kong
-
Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer Br. J. Cancer (IF 8.8) Pub Date : 2024-04-10 John Alexander, Koen Schipper, Sarah Nash, Rachel Brough, Harriet Kemp, Jacopo Iacovacci, Clare Isacke, Rachael Natrajan, Elinor Sawyer, Christopher J. Lord, Syed Haider
-
Trajectory patterns and cumulative burden of CEA during follow-up with non-small cell lung cancer outcomes: A retrospective longitudinal cohort study Br. J. Cancer (IF 8.8) Pub Date : 2024-04-09 Chunxia Li, Lizhu Liu, Ruimin You, Yanli Li, Hongjiang Pu, Ming Lei, Bingbing Fan, Jiali Lv, Mengmei Liu, Guanghong Yan, Zhenhui Li, Dingyun You, Tao Zhang
-
Dynamic genomic changes in methotrexate-resistant human cancer cell lines beyond DHFR amplification suggest potential new targets for preventing drug resistance Br. J. Cancer (IF 8.8) Pub Date : 2024-04-09 Xiang-Ning Meng, Jin-Fa Ma, Yang-He Liu, Si-Qing Li, Xu Wang, Jing Zhu, Meng-Di Cai, Hui-Shu Zhang, Tiantian Song, Shukai Xing, Li-Qing Hou, Huan Guo, Xiao-Bo Cui, Jiang Han, Peng Liu, Guo-Hua Ji, Wen-Jing Sun, Jing-Cui Yu, Song-Bin Fu
-
Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome Br. J. Cancer (IF 8.8) Pub Date : 2024-04-06 Layla Mathieson, Lilian Koppensteiner, David A. Dorward, Richard A. O’Connor, Ahsan R. Akram
Background Cancer-associated fibroblasts (CAFs) are a dominant cell type in the stroma of non-small cell lung cancer (NSCLC). Fibroblast heterogeneity reflects subpopulations of CAFs, which can influence prognosis and treatment efficacy. We describe the subtypes of CAFs in NSCLC. Methods Primary human NSCLC resections were assessed by flow cytometry and multiplex immunofluorescence for markers of fibroblast
-
The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers Br. J. Cancer (IF 8.8) Pub Date : 2024-04-06 Chun Wai Ng, Yvonne T. M. Tsang, David M. Gershenson, Kwong-Kwok Wong
Background Other than for breast cancer, endocrine therapy has not been highly effective for gynecologic cancers. Endocrine therapy resistance in estrogen receptor positive gynecologic cancers is still poorly understood. In this retrospective study, we examined the estrogen receptor (ER) signaling pathway activities of breast, ovarian, endometrial, and cervical cancers to identify those that may predict
-
DRP1 inhibition-mediated mitochondrial elongation abolishes cancer stemness, enhances glutaminolysis, and drives ferroptosis in oral squamous cell carcinoma Br. J. Cancer (IF 8.8) Pub Date : 2024-04-06 Zhen Wang, Shouyi Tang, Luyao Cai, Qing Wang, Dan Pan, Yunmei Dong, Hao Zhou, Jing Li, Ning Ji, Xin Zeng, Yu Zhou, Ying-qiang Shen, Qianming Chen
Background Mitochondrial dynamics play a fundamental role in determining stem cell fate. However, the underlying mechanisms of mitochondrial dynamics in the stemness acquisition of cancer cells are incompletely understood. Methods Metabolomic profiling of cells were analyzed by MS/MS. The genomic distribution of H3K27me3 was measured by CUT&Tag. Oral squamous cell carcinoma (OSCC) cells depended on
-
GCN5 mediates DNA-PKcs crotonylation for DNA double-strand break repair and determining cancer radiosensitivity Br. J. Cancer (IF 8.8) Pub Date : 2024-04-04 Yang Han, Hongling Zhao, Gang Li, Jin Jia, Hejiang Guo, Jinpeng Tan, Xingyao Sun, Saiyu Li, Qian Ran, Chenjun Bai, Yongqing Gu, ZhongJun Li, Hua Guan, Shanshan Gao, Ping-Kun Zhou
Background DNA double-strand break (DSB) induction and repair are important events for determining cell survival and the outcome of cancer radiotherapy. The DNA-dependent protein kinase (DNA-PK) complex functions at the apex of DSBs repair, and its assembly and activity are strictly regulated by post-translation modifications (PTMs)-associated interactions. However, the PTMs of the catalytic subunit
-
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION Br. J. Cancer (IF 8.8) Pub Date : 2024-04-04 Terufumi Kato, James Chih-Hsin Yang, Myung-Ju Ahn, Hiroshi Sakai, Masahiro Morise, Yuh-Min Chen, Ji-Youn Han, Jin-Ji Yang, Jun Zhao, Te-Chun Hsia, Karin Berghoff, Rolf Bruns, Helene Vioix, Simone Lang, Andreas Johne, Xiuning Le, Paul K. Paik
Background Tepotinib, a MET inhibitor approved for the treatment of MET exon 14 (METex14) skipping NSCLC, demonstrated durable clinical activity in VISION (Cohort A + C; N = 313): objective response rate (ORR) 51.4% (95% CI: 45.8, 57.1); median duration of response (mDOR) 18.0 months (95% CI: 12.4, 46.4). We report outcomes in Asian patients from VISION (Cohort A + C) (cut-off: November 20, 2022).
-
Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk Br. J. Cancer (IF 8.8) Pub Date : 2024-04-01 Yu Tian, Yi Lin, Conghui Qu, Volker Arndt, James W. Baurley, Sonja I. Berndt, Stephanie A. Bien, D. Timothy Bishop, Hermann Brenner, Daniel D. Buchanan, Arif Budiarto, Peter T. Campbell, Robert Carreras-Torres, Graham Casey, Andrew T. Chan, Rui Chen, Xuechen Chen, David V. Conti, Virginia Díez-Obrero, Niki Dimou, David A. Drew, Jane C. Figueiredo, Steven Gallinger, Graham G. Giles, Stephen B. Gruber
Background Menopausal hormone therapy (MHT), a common treatment to relieve symptoms of menopause, is associated with a lower risk of colorectal cancer (CRC). To inform CRC risk prediction and MHT risk-benefit assessment, we aimed to evaluate the joint association of a polygenic risk score (PRS) for CRC and MHT on CRC risk. Methods We used data from 28,486 postmenopausal women (11,519 cases and 16,967
-
Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity Br. J. Cancer (IF 8.8) Pub Date : 2024-03-30 Masaaki Akai, Kazuhiro Noma, Takuya Kato, Seitaro Nishimura, Hijiri Matsumoto, Kento Kawasaki, Tomoyoshi Kunitomo, Teruki Kobayashi, Noriyuki Nishiwaki, Hajime Kashima, Satoru Kikuchi, Toshiaki Ohara, Hiroshi Tazawa, Peter L. Choyke, Hisataka Kobayashi, Toshiyoshi Fujiwara
Background Cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME) play a critical role in tumor immunosuppression. However, targeted depletion of CAFs is difficult due to their diverse cells of origin and the resulting lack of specific surface markers. Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer treatment that leads to rapid cell membrane damage. Methods In this study
-
Oesophageal cancer awareness and anticipated time to help-seeking: results from a population-based survey Br. J. Cancer (IF 8.8) Pub Date : 2024-03-30 Jasmijn Sijben, Lotte J. Huibertse, Linda Rainey, Mireille J. M. Broeders, Yonne Peters, Peter D. Siersema
Background Modifying public awareness of oesophageal cancer symptoms might help to decrease late-stage diagnosis and, in turn, improve cancer outcomes. This study aimed to explore oesophageal cancer symptom awareness and determinants of lower awareness and anticipated time to help-seeking. Methods We invited 18,156 individuals aged 18 to 75 years using random sampling of the nationwide Dutch population
-
Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification Br. J. Cancer (IF 8.8) Pub Date : 2024-03-29 Xiaoxiao Hu, Yilu Zhou, Charlotte Hill, Kai Chen, Cheng Cheng, Xiaowei Liu, Peiwen Duan, Yaoyao Gu, Yeming Wu, Rob M. Ewing, Zhongrong Li, Zhixiang Wu, Yihua Wang
Background Despite the extensive study of MYCN-amplified neuroblastomas, there is a significant unmet clinical need in MYCN non-amplified cases. In particular, the extent of heterogeneity within the MYCN non-amplified population is unknown. Methods A total of 1566 samples from 16 datasets were identified in Gene Expression Omnibus (GEO) and ArrayExpress. Characterisation of the subtypes was analysed
-
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients Br. J. Cancer (IF 8.8) Pub Date : 2024-03-26 Alicja Puszkiel, Guillaume Bianconi, Blaise Pasquiers, David Balakirouchenane, Jennifer Arrondeau, Pascaline Boudou-Rouquette, Marie-Claire Bretagne, Joe-Elie Salem, Xavier Declèves, Michel Vidal, Nora Kramkimel, Sarah Guegan, Selim Aractingi, Olivier Huillard, Jérôme Alexandre, Marie Wislez, François Goldwasser, Benoit Blanchet
-
Methylation analysis of DCC gene in saliva samples is an efficient method for non-invasive detection of superficial hypopharyngeal cancer Br. J. Cancer (IF 8.8) Pub Date : 2024-03-27 Ryosuke Hirai, Hideaki Kinugasa, Shumpei Yamamoto, Soichiro Ako, Koichiro Tsutsumi, Makoto Abe, Koji Miyahara, Masahiro Nakagawa, Motoyuki Otsuka
-
Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications Br. J. Cancer (IF 8.8) Pub Date : 2024-03-26 Juan Carlos Laguna, Belén Pastor, Irene Nalda, Sara Hijazo-Pechero, Cristina Teixido, Miriam Potrony, Joan Antón Puig-Butillé, Laura Mezquita
-
Identification of unique rectal cancer-specific subtypes Br. J. Cancer (IF 8.8) Pub Date : 2024-03-26 Batuhan Kisakol, Anna Matveeva, Manuela Salvucci, Alexander Kel, Elizabeth McDonough, Fiona Ginty, Daniel B. Longley, Jochen H. M. Prehn
-
Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma Br. J. Cancer (IF 8.8) Pub Date : 2024-03-22 Nick Landman, Danielle Hulsman, Jitendra Badhai, Jawahar Kopparam, Julian Puppe, Gaurav Kumar Pandey, Maarten van Lohuizen
-
Persistence of peripheral CD8 + CD28− T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer Br. J. Cancer (IF 8.8) Pub Date : 2024-03-22 Xiaoran Liu, Xiangming Cheng, Feng Xie, Kun Li, Yongcan Shi, Bin Shao, Xu Liang, Fengling Wan, Shidong Jia, Yue Zhang, Yiqiang Liu, Huiping Li
-
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer Br. J. Cancer (IF 8.8) Pub Date : 2024-03-22 Koji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, Kenji Sawa, Yoshimasa Shiraishi, Ryota Saito, Junko Tanizaki, Yosuke Tamura, Akito Hata, Kosuke Tsuruno, Tomohiro Sakamoto, Shunsuke Teraoka, Masahide Oki, Hiroshi Watanabe, Takaaki Tokito, Kenji Nagata, Takeshi Masuda, Yasushi Nakamura, Kazuko Sakai, Yasutaka Chiba, Akihiko Ito, Kazuto Nishio, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Hidetoshi Hayashi
-
Radiation therapy with phenotypic medicine: towards N-of-1 personalization Br. J. Cancer (IF 8.8) Pub Date : 2024-03-21 Li Ming Chong, Peter Wang, V. Vien Lee, Smrithi Vijayakumar, Hong Qi Tan, Fu Qiang Wang, Teri Danielle You Ying Yeoh, Anh T. L. Truong, Lester Wen Jeit Tan, Shi Bei Tan, Kirthika Senthil Kumar, Eric Hau, Balamurugan A. Vellayappan, Agata Blasiak, Dean Ho
-
Routes to diagnosis for hepatocellular carcinoma patients: predictors and associations with treatment and mortality Br. J. Cancer (IF 8.8) Pub Date : 2024-03-18 Anya Burton, Jennifer Wilburn, Robert J. Driver, David Wallace, Sean McPhail, Tim J. S. Cross, Ian A. Rowe, Aileen Marshall
-
Multivitamin use after diagnosis and prostate cancer survival among men with nonmetastatic prostate cancer Br. J. Cancer (IF 8.8) Pub Date : 2024-03-15 Yiwen Zhang, Konrad H. Stopsack, Kana Wu, Mingyang Song, Lorelei A. Mucci, Edward Giovannucci
Background Multivitamin use is common among cancer patients. Whether post-diagnostic multivitamin supplementation is beneficial for prostate cancer survival is largely unknown, and some evidence even suggests potential harm. Methods We prospectively assessed post-diagnostic multivitamin use in relation to prostate cancer survival among 4756 men with nonmetastatic prostate cancer at diagnosis in the
-
Transforming post pandemic cancer services Br. J. Cancer (IF 8.8) Pub Date : 2024-03-15 Thomas Round, Lakshman Sethuraman, Mark Ashworth, Arnie Purushotham
-
Functional proteomics of colon cancer Consensus Molecular Subtypes Br. J. Cancer (IF 8.8) Pub Date : 2024-03-14 Jaime Feliu, Angelo Gámez-Pozo, Daniel Martínez-Pérez, Pablo Pérez-Wert, Daniel Matamala-Luengo, David Viñal, Laura Kunz, Rocío López- Vacas, Antje Dittmann, Nuria Rodríguez-Salas, Ana Custodio, Juan Ángel Fresno Vara, Lucía Trilla-Fuertes
-
Circulating 25-hydroxyvitamin D and survival outcomes of colorectal cancer: evidence from population-based prospective cohorts and Mendelian randomisation Br. J. Cancer (IF 8.8) Pub Date : 2024-03-13 Xiaomeng Zhang, Yazhou He, Xue Li, Rasha Shraim, Wei Xu, Lijuan Wang, Susan M. Farrington, Harry Campbell, Maria Timofeeva, Lina Zgaga, Peter Vaughan-Shaw, Evropi Theodoratou, Malcolm G. Dunlop
-
Single-cell RNA sequencing analysis of vestibular schwannoma reveals functionally distinct macrophage subsets Br. J. Cancer (IF 8.8) Pub Date : 2024-03-13 Paramita Baruah, Christopher Mahony, Jennifer L. Marshall, Charlotte G. Smith, Peter Monksfield, Richard I. Irving, Ingrid E. Dumitriu, Christopher D. Buckley, Adam P. Croft
-
Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial Br. J. Cancer (IF 8.8) Pub Date : 2024-03-12 Jinlin Cai, Kaixin Lin, Tongfeng Luo, Jingrong Weng, Haotian Liu, Ze Yuan, Zixiao Wan, Junyi Han, Jinxin Lin, Xiaoxia Liu, Xiaolin Wang, Meijin Huang, Yanxin Luo, Huichuan Yu
-
RNA expression of 6 genes from metastatic mucosal gastric cancer serves as the global prognostic marker for gastric cancer with functional validation Br. J. Cancer (IF 8.8) Pub Date : 2024-03-11 Yun-Suhk Suh, Jieun Lee, Joshy George, Donghyeok Seol, Kyoungyun Jeong, Seung-Young Oh, Chanmi Bang, Yukyung Jun, Seong-Ho Kong, Hyuk-Joon Lee, Jong-Il Kim, Woo Ho Kim, Han-Kwang Yang, Charles Lee
-
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells Br. J. Cancer (IF 8.8) Pub Date : 2024-03-11 Anxo Rio-Vilariño, Aiora Cenigaonandia-Campillo, Ana García-Bautista, Pedro A. Mateos-Gómez, Marina I. Schlaepfer, Laura del Puerto-Nevado, Oscar Aguilera, Laura García-García, Carlos Galeano, Irene de Miguel, Juana Serrano-López, Natalia Baños, María Jesús Fernández-Aceñero, Juan Carlos Lacal, Enzo Medico, Jesús García-Foncillas, Arancha Cebrián
-
Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme Br. J. Cancer (IF 8.8) Pub Date : 2024-03-11 Daniëlle E. ten Velde, Lucien E. M. Duijm, Maurice J. C. van der Sangen, Robert-Jan Schipper, Vivianne C. G. Tjan-Heijnen, Willem Vreuls, Luc J. A. Strobbe, Adri C. Voogd
-
Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions Br. J. Cancer (IF 8.8) Pub Date : 2024-03-09 M. Medrano, M. Contreras, T. Caballero-Velázquez, L. Martínez, J. A. Bejarano-García, R. Calderón-Ruiz, C. B. García-Calderón, I. V. Rosado, J. A. Pérez-Simón
-
Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis Br. J. Cancer (IF 8.8) Pub Date : 2024-03-09 Masataka Yokode, Masahiro Shiokawa, Hisato Kawakami, Takeshi Kuwada, Yoshihiro Nishikawa, Yuya Muramoto, Hiroki Kitamoto, Makoto Okabe, Hajime Yamazaki, Norihiro Okamoto, Toshihiro Morita, Kazuya Ohno, Risa Nakanishi, Ikuhisa Takimoto, Muneji Yasuda, Koki Chikugo, Shimpei Matsumoto, Hiroyuki Yoshida, Sakiko Ota, Takeharu Nakamura, Hirokazu Okada, Tomonori Hirano, Nobuyuki Kakiuchi, Tomoaki Matsumori
-
Platelets induce CD39 expression in tumor cells to facilitate tumor metastasis Br. J. Cancer (IF 8.8) Pub Date : 2024-03-09 Zhaochen Ning, Keyan Liu, Hui Zhang, Guanjun Dong, Xiaotong Wang, Huabao Xiong
-
EIF4A3-negatively driven circular RNA β-catenin (circβ-catenin) promotes colorectal cancer progression via miR-197-3p/CTNND1 regulatory axis Br. J. Cancer (IF 8.8) Pub Date : 2024-03-08 Li-Qiang Deng, Chuan-Jian Shi, Shu-Ting Zhou, Wei-Qiang Zeng, Yan-Fang Xian, Yu-Yan Wang, Wei-Ming Fu, Han-Li Lin, Wei Liu, Jin-Fang Zhang
-
Pirfenidone alleviates fibrosis by acting on tumour–stroma interplay in pancreatic cancer Br. J. Cancer (IF 8.8) Pub Date : 2024-03-07 Yalan Lei, Jin Xu, Mingming Xiao, Di Wu, He Xu, Jing Yang, Xiaoqi Mao, Haoqi Pan, Xianjun Yu, Si Shi
-
PRRX1-TOP2A interaction is a malignancy-promoting factor in human malignant peripheral nerve sheath tumours Br. J. Cancer (IF 8.8) Pub Date : 2024-03-06 Shota Takihira, Daisuke Yamada, Tatsunori Osone, Tomoka Takao, Masakiyo Sakaguchi, Michiyuki Hakozaki, Takuto Itano, Eiji Nakata, Tomohiro Fujiwara, Toshiyuki Kunisada, Toshifumi Ozaki, Takeshi Takarada
-
A metabolic map and artificial intelligence-aided identification of nasopharyngeal carcinoma via a single-cell Raman platform Br. J. Cancer (IF 8.8) Pub Date : 2024-03-07 Jiabao Xu, Dayang Chen, Wei Wu, Xiang Ji, Xiaowen Dou, Xiaojuan Gao, Jian Li, Xiuming Zhang, Wei E. Huang, Dan Xiong
-
Shifting the paradigm in the management of early prostate cancer Br. J. Cancer (IF 8.8) Pub Date : 2024-03-06 Vincent Gnanapragasam
Outcomes from active surveillance have clearly shown that it is the optimal method of managing many early prostate cancers. Yet, clinician training and healthcare systems are still primarily focused on the “need to treat”. This comment explores the challenges and resource issues in future implementation of high-quality surveillance programmes.
-
Early onset pancreatic cancer—exploring contemporary treatment and outcomes using real-world data Br. J. Cancer (IF 8.8) Pub Date : 2024-03-06 Shehara Mendis, Lara Lipton, Yat Hang To, Sumitra Ananda, Michael Michael, Sue-Anne McLachlan, Benjamin Thomson, Benjamin Loveday, Brett Knowles, Adrian Fox, Mehrdad Nikfarjam, Val Usatoff, Julia Shapiro, Kate Clarke, Sharon Pattison, Cheng Ean Chee, Rob Zielinski, Rachel Wong, Peter Gibbs, Belinda Lee
-
Risk and adverse clinical outcomes of thrombocytopenia among patients with solid tumors—a Danish population-based cohort study Br. J. Cancer (IF 8.8) Pub Date : 2024-03-06 Kasper Adelborg, Katalin Veres, Erzsébet Horváth-Puhó, Mary Clouser, Hossam Saad, Henrik Toft Sørensen
-
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma Br. J. Cancer (IF 8.8) Pub Date : 2024-03-04 Yusuke Matoba, Dominique T. Zarrella, Venkatesh Pooladanda, Maryam Azimi Mohammadabadi, Eugene Kim, Shaan Kumar, Mengyao Xu, Xingping Qin, Lauren J Ray, Kyle M. Devins, Raj Kumar, Artem Kononenko, Eric Eisenhauer, Irva E. Veillard, Wataru Yamagami, Sarah J. Hill, Kristopher A. Sarosiek, Oladapo O. Yeku, David R. Spriggs, Bo R. Rueda
-
A cellular model provides insights into the pathogenicity of the oncogenic FOXL2 somatic variant p.Cys134Trp Br. J. Cancer (IF 8.8) Pub Date : 2024-03-01 Laetitia Herman, Angélique Amo, Berangère Legois, Caterina Di Carlo, Reiner A. Veitia, Anne-Laure Todeschini
-
Redefining cancer research for therapeutic breakthroughs Br. J. Cancer (IF 8.8) Pub Date : 2024-02-29 Arseniy E. Yuzhalin
-
Solar ultraviolet radiation exposure, and incidence of childhood acute lymphocytic leukaemia and non-Hodgkin lymphoma in a US population-based dataset Br. J. Cancer (IF 8.8) Pub Date : 2024-02-29 Mark P. Little, Jim Z. Mai, Michelle Fang, Pavel Chernyavskiy, Victoria Kennerley, Elizabeth K. Cahoon, Myles G. Cockburn, Gerald M. Kendall, Michael G. Kimlin
-
Single-cell RNA sequencing reveals myeloid and T cell co-stimulation mediated by IL-7 anti-cancer immunotherapy Br. J. Cancer (IF 8.8) Pub Date : 2024-02-29 Hye Hyeon Eum, Dasom Jeong, Nayoung Kim, Areum Jo, Minsu Na, Huiram Kang, Yourae Hong, Jin-Sun Kong, Gi Heon Jeong, Seung-Ah Yoo, Hae-Ock Lee
-
Ranolazine: a potential anti-metastatic drug targeting voltage-gated sodium channels Br. J. Cancer (IF 8.8) Pub Date : 2024-02-29 Mustafa B. A. Djamgoz
Background Multi-faceted evidence from a range of cancers suggests strongly that de novo expression of voltage-gated sodium channels (VGSCs) plays a significant role in driving cancer cell invasiveness. Under hypoxic conditions, common to growing tumours, VGSCs develop a persistent current (INaP) which can be blocked selectively by ranolazine. Methods Several different carcinomas were examined. We
-
Comment on “Dexamethasone-sparing on days 2–4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)” Br. J. Cancer (IF 8.8) Pub Date : 2024-02-26 Luigi Celio, Andrea Antonuzzo, Matti S. Aapro
Minatogawa et al. [1] should be commended for conducting this important trial. Antiemetic guidelines devised from the major international organizations recommend now olanzapine as a fixed part of a four-drug prophylactic regimen in the setting of highly emetogenic chemotherapy (HEC) [2, 3]. In light of this, it is clinically relevant that a four-drug regimen containing olanzapine, palonosetron, a neurokinin-1
-
Risk of cancer and serious disease in Danish patients with urgent referral for serious non-specific symptoms and signs of cancer in Funen 2014–2021 Br. J. Cancer (IF 8.8) Pub Date : 2024-02-26 Rasmus Birkholm Grønnemose, Per Syrak Hansen, Søren Worsøe Laursen, Oke Gerke, Jakob Kjellberg, Jesper Lykkegaard, Clara Thye-Rønn, Poul Flemming Høilund-Carlsen, Peter Thye-Rønn
-
A prospective study of birth weight and prostate cancer risk and mortality in the Health Professionals Follow-up Study Br. J. Cancer (IF 8.8) Pub Date : 2024-02-22 Qinran Liu, Yiwen Zhang, Jane B. Vaselkiv, Lorelei A. Mucci, Edward L. Giovannucci, Elizabeth A. Platz, Siobhan Sutcliffe
Background Previous studies have observed inconsistent associations between birth weight and aggressive prostate cancer risk. This study aimed to prospectively analyse this association in the Health Professionals Follow-up Study (HPFS). Methods Birth weight was self-reported in 1994, and prostate cancer diagnoses were assessed biennially through January 2017 and confirmed by medical record review.
-
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database Br. J. Cancer (IF 8.8) Pub Date : 2024-02-24 C. S. Karapetis, H. Liu, M. J. Sorich, L. D. Pederson, E. Van Cutsem, T. Maughan, J. Y. Douillard, C. J. O’Callaghan, D. Jonker, C. Bokemeyer, A. Sobrero, C. Cremolini, B. Chibaudel, J. Zalcberg, R. Adams, M. Buyse, M. Peeters, T. Yoshino, A. de Gramont, Q. Shi
-
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer Br. J. Cancer (IF 8.8) Pub Date : 2024-02-23 Cath Eberlein, Stuart C. Williamson, Lorna Hopcroft, Susana Ros, Jennifer I. Moss, James Kerr, Wytske M. van Weerden, Elza C. de Bruin, Shanade Dunn, Brandon Willis, Sarah J. Ross, Claire Rooney, Simon T. Barry
-
Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro Br. J. Cancer (IF 8.8) Pub Date : 2024-02-23 Qiyu Cao, Annika Hajosch, Richard Eric Kast, Christopher Loehmann, Michal Hlavac, Pamela Fischer-Posovszky, Hannah Strobel, Mike-Andrew Westhoff, Markus D. Siegelin, Christian Rainer Wirtz, Marc-Eric Halatsch, Georg Karpel-Massler